FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3135543818> ?p ?o ?g. }

• W3135543818 endingPage "3948" @default.
• W3135543818 startingPage "3938" @default.
• W3135543818 abstract "In 2008, the US Food and Drug Administration (FDA) issued a guidance requiring that cardiovascular outcome trials (CVOTs) be conducted for newer hypoglycaemic drugs for type 2 diabetes (T2D). We aimed to examine the decisions by 3 regulatory authorities in response to identical CVOT data.We surveyed ClinicalTrials.gov to identify CVOTs and examined the revision histories of drug labels in databases from the FDA, the European Medicines Agency, and the Pharmaceuticals and Medical Devices Agency in Japan.We selected 14 drugs and corresponding CVOTs, 12 of which were conducted as postmarketing trials. In the USA and the EU, the pre-CVOT indication on all 14 labels was improvement in glycaemic control. Six drugs showed significant cardiovascular risk reduction, which led to an additional indication regarding reduction of cardiovascular adverse events in the USA, and a change to the EU indication to specify treatment of adults with T2D. The initial indication in Japan, T2D, remained unchanged. Regarding safety, significant increases in heart failure were observed only in the saxagliptin trial. A warning was added to the saxagliptin labels in the EU and Japan, whereas the FDA required a class effect warning to be added to the labels of all 4 dipeptidyl peptidase-4 inhibitors.Regulatory authorities using identical trial data made substantially different decisions regarding both safety and efficacy of hypoglycaemic drugs. The differences in initial indication wording between Japan and the other authorities suggest that trial data and T2D are interpreted differently in these regions." @default.
• W3135543818 created "2021-03-15" @default.
• W3135543818 creator A5010210218 @default.
• W3135543818 creator A5089633475 @default.
• W3135543818 date "2021-03-31" @default.
• W3135543818 modified "2023-10-16" @default.
• W3135543818 title "Approvals of type 2 diabetes drugs tested in cardiovascular outcome trials: A tripartite comparison" @default.
• W3135543818 cites W1545327744 @default.
• W3135543818 cites W2041298800 @default.
• W3135543818 cites W2064130493 @default.
• W3135543818 cites W2064322421 @default.
• W3135543818 cites W2073935789 @default.
• W3135543818 cites W2078089300 @default.
• W3135543818 cites W2127125241 @default.
• W3135543818 cites W2127854619 @default.
• W3135543818 cites W2142830692 @default.
• W3135543818 cites W2146264128 @default.
• W3135543818 cites W2165815833 @default.
• W3135543818 cites W2188846692 @default.
• W3135543818 cites W2224881840 @default.
• W3135543818 cites W2282578582 @default.
• W3135543818 cites W2306356166 @default.
• W3135543818 cites W2425644022 @default.
• W3135543818 cites W2519510391 @default.
• W3135543818 cites W2582793111 @default.
• W3135543818 cites W2626446274 @default.
• W3135543818 cites W2754041380 @default.
• W3135543818 cites W2767087620 @default.
• W3135543818 cites W2779223875 @default.
• W3135543818 cites W2790815880 @default.
• W3135543818 cites W2794293252 @default.
• W3135543818 cites W2894746763 @default.
• W3135543818 cites W2900149048 @default.
• W3135543818 cites W2900413769 @default.
• W3135543818 cites W2909659307 @default.
• W3135543818 cites W2916269741 @default.
• W3135543818 cites W2948612418 @default.
• W3135543818 cites W2961900003 @default.
• W3135543818 cites W2970624317 @default.
• W3135543818 cites W2987510459 @default.
• W3135543818 cites W2987689504 @default.
• W3135543818 cites W2989589082 @default.
• W3135543818 cites W3020611265 @default.
• W3135543818 cites W4206445899 @default.
• W3135543818 doi "https://doi.org/10.1111/bcp.14814" @default.
• W3135543818 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33704809" @default.
• W3135543818 hasPublicationYear "2021" @default.
• W3135543818 type Work @default.
• W3135543818 sameAs 3135543818 @default.
• W3135543818 citedByCount "0" @default.
• W3135543818 crossrefType "journal-article" @default.
• W3135543818 hasAuthorship W3135543818A5010210218 @default.
• W3135543818 hasAuthorship W3135543818A5089633475 @default.
• W3135543818 hasBestOaLocation W31355438181 @default.
• W3135543818 hasConcept C126322002 @default.
• W3135543818 hasConcept C134018914 @default.
• W3135543818 hasConcept C156490143 @default.
• W3135543818 hasConcept C177713679 @default.
• W3135543818 hasConcept C197934379 @default.
• W3135543818 hasConcept C2776876202 @default.
• W3135543818 hasConcept C2777180221 @default.
• W3135543818 hasConcept C2778176773 @default.
• W3135543818 hasConcept C2779284873 @default.
• W3135543818 hasConcept C2780012697 @default.
• W3135543818 hasConcept C2780035454 @default.
• W3135543818 hasConcept C2780282729 @default.
• W3135543818 hasConcept C3018890749 @default.
• W3135543818 hasConcept C535046627 @default.
• W3135543818 hasConcept C555293320 @default.
• W3135543818 hasConcept C71924100 @default.
• W3135543818 hasConcept C98274493 @default.
• W3135543818 hasConceptScore W3135543818C126322002 @default.
• W3135543818 hasConceptScore W3135543818C134018914 @default.
• W3135543818 hasConceptScore W3135543818C156490143 @default.
• W3135543818 hasConceptScore W3135543818C177713679 @default.
• W3135543818 hasConceptScore W3135543818C197934379 @default.
• W3135543818 hasConceptScore W3135543818C2776876202 @default.
• W3135543818 hasConceptScore W3135543818C2777180221 @default.
• W3135543818 hasConceptScore W3135543818C2778176773 @default.
• W3135543818 hasConceptScore W3135543818C2779284873 @default.
• W3135543818 hasConceptScore W3135543818C2780012697 @default.
• W3135543818 hasConceptScore W3135543818C2780035454 @default.
• W3135543818 hasConceptScore W3135543818C2780282729 @default.
• W3135543818 hasConceptScore W3135543818C3018890749 @default.
• W3135543818 hasConceptScore W3135543818C535046627 @default.
• W3135543818 hasConceptScore W3135543818C555293320 @default.
• W3135543818 hasConceptScore W3135543818C71924100 @default.
• W3135543818 hasConceptScore W3135543818C98274493 @default.
• W3135543818 hasFunder F4320334764 @default.
• W3135543818 hasIssue "10" @default.
• W3135543818 hasLocation W31355438181 @default.
• W3135543818 hasLocation W31355438182 @default.
• W3135543818 hasOpenAccess W3135543818 @default.
• W3135543818 hasPrimaryLocation W31355438181 @default.
• W3135543818 hasRelatedWork W2041342486 @default.
• W3135543818 hasRelatedWork W2049010416 @default.
• W3135543818 hasRelatedWork W2146774087 @default.
• W3135543818 hasRelatedWork W2329993151 @default.

• next